Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53

Lenalidomide has demonstrated clinical activity in patients with chronic lymphocytic leukemia (CLL), even though it is not cytotoxic for primary CLL cells in vitro. We examined the direct effect of lenalidomide on CLL-cell proliferation induced by CD154-expressing accessory cells in media containing...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Fecteau, Jessie-F., Corral, Laura G., Ghia, Emanuela M., Gaidarova, Svetlana, Futalan, Diahnn, Bharati, Ila Sri, Cathers, Brian, Schwaederlé, Maria, Cui, Bing, Lopez-Girona, Antonia, Messmer, Davorka, Kipps, Thomas J.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2014
Témata:
Lymphoid Neoplasia
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4155272/
https://ncbi.nlm.nih.gov/pubmed/24990888
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-03-559591
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky